컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

European Society for Medical Oncology Asia Congress 2024 (ESMO Asia 2024)

6 Dec - 8 Dec, 2024, Singapore

Alectinib trumps crizotinib for ALK+ NSCLC

2025-01-10

In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naive, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).
KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

2025-01-10

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.
LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

2025-01-10

Treatment with belzutifan improves progression-free survival (PFS) and objective response rate (ORR) in East Asian patients with advanced clear-cell renal cell carcinoma (RCC) compared with everolimus, according to the updated subgroup data of the phase III LITESPARK-005 trial presented at ESMO Asia 2024.
Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC

2025-01-10

First-line treatment with osimertinib plus platinum-pemetrexed chemotherapy (CTx) induces significant improvements in progression-free survival (PFS) among Asian patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), which is similar with the results seen in the global population of the FLAURA2 study.
PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

2025-01-10

For Asian patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) delivery of amivantamab plus lazertinib does not alter the drug’s pharmacokinetic and efficacy profile compared with the intravenous (IV) approach and is associated with fewer infusion-related reactions, according to a subgroup analysis of the phase III PALOMA-3 trial.
Retifanlimab plus chemo improves survival in metastatic NSCLC

2025-01-10

The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.
Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

2025-01-10

The combination of rezvilutamide plus androgen-deprivation therapy (ADT) proves to be efficacious and well-tolerated in the treatment of patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) across all age groups, according to a post hoc analysis of the phase III CHART trial.
Survival benefit with STRIDE for HCC sustained at 5 years

2025-01-10

The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).
Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

2025-01-10

With the follow-up extended for an additional year, the RATIONALE-309 trial demonstrates a continued PFS advantage following the addition of tislelizumab to chemo for the 1L treatment of recurrent/metastatic NPC, as shown in the 3-year follow-up results presented at ESMO Asia 2024

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브